Nabriva reports successful Phase I clinical trial for BC-3781
Studies presented at ECCMID alongside other papers relating to Nabriva’s pleuromutilin pipeline
Nabriva Therapeutics announced that it has successfully completed a series of Phase I clinical trials of its pleuromutilin antibiotic, BC-3781. BC-3781 is being developed for intravenous and oral treatment of skin and skin structure infections (SSSI) and community-acquired pneumonia (CAP). Data from some of these Phase I trials is being presented at the 20th European Congress of Clinical microbiology and infectious diseases (ECCMID) in Vienna.
The results of the clinical trials which began in July 2009 demonstrate that BC-3781 was safe and well tolerated up to the maximum doses tested. BC-3781 exhibits predictable pharmacokinetics in humans and the plasma levels achieved show that it has therapeutic potential for the treatment of skin and lung infections caused by bacteria. Nabriva will now progress BC-3781 into Phase II studies.
Dr. David Chiswell, CEO of Nabriva Therapeutics said: "BC-3781 is the first pleuromutilin to demonstrate safety, tolerability and therapeutic drug levels when administered systemically in humans. The phase I data show that BC-3781 can be delivered either orally or by intravenous infusion and that it has real potential to treat serious bacterial infections including those caused by organisms resistant to other antibiotics including MRSA and MDRP. We look forward to advancing clinical development into Phase II trials shortly.”
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

The farm effect: antiallergic properties of the cow’s milk protein BLG - The milk protein is also found in stable dust and ambient air: Together with its binding partners, BLG may contribute to the protection against asthma and allergies
Young killer cells protect against infectious mononucleosis

Stardust in the bathroom - Nanoceramics: novel treatment for skin diseases

Atherosclerosis: How diseased blood vessels communicate with the brain - LMU scientists have been able to demonstrate for the first time that nerve signals are exchanged between arteries and the brain in atherosclerosis
5 Leading Multinationals Announce R&D Projects for Ireland - Bristol-Myers Squibb Company, Pfizer Inc., Genzyme Corporation, Xilinx Inc. Citigroup are investing a total of EUR 53.25 million

Developmental protein plays role in spread of cancer
